TNFRSF18 and neoplasm: ADAM10 was mutually exclusive with numerous tumor immune checkpoints, including EGFB, LAG3, IL4, TNFRSF18, TNFRSF4, TNFRSF14, CD27 and CCL5, which further suggests that ADAM10 may be a novel target for tumor immunotherapy with good potential.